Does the media prefer ATRA or ORIC?

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Atara Biotherapeutics' score of 0.93 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ATRA or CMPX?

In the previous week, Compass Therapeutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Compass Therapeutics' score of 0.57 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LXEO or ATRA?

In the previous week, Lexeo Therapeutics had 8 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 9 mentions for Lexeo Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Lexeo Therapeutics' score of -0.21 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ATRA or AVIR?

Atara Biotherapeutics presently has a consensus target price of $9.50, indicating a potential downside of 18.45%. Given Atara Biotherapeutics' higher possible upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Atara Biotherapeutics (ATRA) Competitors

$11.65 +0.28 (+2.46%)

As of 07/2/2026 04:00 PM Eastern

Compare

ATRA vs. ORIC, CMPX, LXEO, UPB, and AVIR

Should you buy Atara Biotherapeutics stock or one of its competitors? MarketBeat compares Atara Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Compass Therapeutics (CMPX), Lexeo Therapeutics (LXEO), Upstream Bio (UPB), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Atara Biotherapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Oric Pharmaceuticals' return on equity of -35.33% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Atara Biotherapeutics' score of 0.93 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 18.45%. Oric Pharmaceuticals has a consensus target price of $18.92, suggesting a potential upside of 62.51%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Compass Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Compass Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Compass Therapeutics' return on equity of -39.75% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Compass Therapeutics	N/A	-39.75%	-35.29%

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Atara Biotherapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 18.45%. Compass Therapeutics has a consensus target price of $12.25, suggesting a potential upside of 439.65%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Atara Biotherapeutics has higher revenue and earnings than Compass Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Compass Therapeutics	$850K	480.95	-$66.49M	-$0.41	N/A

In the previous week, Compass Therapeutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Compass Therapeutics' score of 0.57 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Lexeo Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Lexeo Therapeutics' return on equity of -47.48% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Lexeo Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Lexeo Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 299.79%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 18.45%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atara Biotherapeutics has higher revenue and earnings than Lexeo Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A

In the previous week, Lexeo Therapeutics had 8 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 9 mentions for Lexeo Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Lexeo Therapeutics' score of -0.21 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Upstream Bio?

Atara Biotherapeutics (NASDAQ:ATRA) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Atara Biotherapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential downside of 18.45%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 341.63%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 1 mentions for Atara Biotherapeutics and 0 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.78 beat Atara Biotherapeutics' score of 0.93 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Upstream Bio	Very Positive

Atara Biotherapeutics has higher revenue and earnings than Upstream Bio. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Upstream Bio	$2.85M	143.40	-$143.44M	-$2.91	N/A

Atara Biotherapeutics has a net margin of -40.91% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Summary

Atara Biotherapeutics and Upstream Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 1 mentions for Atara Biotherapeutics and 0 mentions for Atea Pharmaceuticals. Atara Biotherapeutics' average media sentiment score of 0.93 beat Atea Pharmaceuticals' score of 0.47 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Atea Pharmaceuticals	Neutral

Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Atea Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atea Pharmaceuticals' return on equity of -57.01% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Atara Biotherapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Atara Biotherapeutics presently has a consensus target price of $9.50, indicating a potential downside of 18.45%. Given Atara Biotherapeutics' higher possible upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Atara Biotherapeutics beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$102.45M	$3.65B	$6.82B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	6.63%
P/E Ratio	-17.39	21.43	27.66	24.67
Price / Sales	0.87	322.62	532.53	95.45
Price / Cash	2.34	143.20	48.59	58.15
Price / Book	-2.18	8.66	11.07	6.45
Net Income	$32.69M	$23.81M	$3.57B	$336.71M
7 Day Performance	10.85%	3.47%	2.23%	1.37%
1 Month Performance	20.98%	8.53%	4.60%	1.67%
1 Year Performance	45.44%	62.64%	33.47%	24.05%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	0.9832 of 5 stars	$11.65 +2.5%	$9.50 -18.5%	+41.2%	$102.45M	$120.77M	N/A	330
ORIC Oric Pharmaceuticals	2.7578 of 5 stars	$10.15 +6.5%	$18.92 +86.4%	+9.3%	$986.53M	N/A	N/A	80	News Coverage Positive News
CMPX Compass Therapeutics	3.0289 of 5 stars	$2.16 +3.8%	$12.91 +497.6%	-13.4%	$374.58M	$850K	N/A	20	Analyst Forecast
LXEO Lexeo Therapeutics	1.7953 of 5 stars	$4.81 +1.3%	$18.75 +289.8%	+7.1%	$372.98M	N/A	N/A	58	News Coverage Insider Trade
UPB Upstream Bio	2.2563 of 5 stars	$6.93 +2.7%	$33.17 +378.6%	-32.5%	$367.33M	$2.85M	N/A	38	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, CMPX, LXEO, UPB, and AVIR

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Summary

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Summary

How does Atara Biotherapeutics compare to Upstream Bio?

Summary

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, CMPX, LXEO, UPB, and AVIR

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Which has more volatility and risk, ATRA or ORIC?

Is ATRA or ORIC more profitable?

Does the media prefer ATRA or ORIC?

Which has stronger earnings and valuation, ATRA or ORIC?

Do insiders & institutionals hold more shares of ATRA or ORIC?

Do analysts recommend ATRA or ORIC?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Is ATRA or CMPX more profitable?

Do institutionals & insiders have more ownership in ATRA or CMPX?

Which has more risk & volatility, ATRA or CMPX?

Do analysts prefer ATRA or CMPX?

Which has higher earnings and valuation, ATRA or CMPX?

Does the media prefer ATRA or CMPX?

Summary

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Is LXEO or ATRA more profitable?

Which has more volatility and risk, LXEO or ATRA?

Do analysts recommend LXEO or ATRA?

Do institutionals & insiders believe in LXEO or ATRA?

Which has higher valuation & earnings, LXEO or ATRA?

Does the media refer more to LXEO or ATRA?

Summary

How does Atara Biotherapeutics compare to Upstream Bio?

Which has more risk and volatility, ATRA or UPB?

Do analysts recommend ATRA or UPB?

Do institutionals & insiders hold more shares of ATRA or UPB?

Does the media refer more to ATRA or UPB?

Which has better earnings and valuation, ATRA or UPB?

Is ATRA or UPB more profitable?

Summary

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Do institutionals and insiders have more ownership in ATRA or AVIR?

Does the media prefer ATRA or AVIR?

Which has more risk and volatility, ATRA or AVIR?

Is ATRA or AVIR more profitable?

Which has preferable earnings & valuation, ATRA or AVIR?

Do analysts rate ATRA or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools